Fundraising FoxHealthtech Startups
18,775 companies tagged Healthtech, with their investors and founders.
PiroGon is developing a closed-loop medical platform, based on technology from Yale University, that detects the backflow and spillover of stomach acid and dynamically restores airway protection to prevent aspiration pneumonia. It targets patients at risk of aspiration across neurologic, surgical, and critical-care settings.
0 investors
0 investors
0 investors
0 investors
0 investors
Plasmology4 develops Plaz4, a non-thermal (cold) plasma technology for medical applications, with its first product, the Plaz4 1000 system, aimed at treating antibiotic-resistant infections and chronic non-healing wounds. It is a pre-revenue medical device company in the emerging field of plasma medicine, and its lead product has received FDA Breakthrough Device designation but is not yet approved for sale.
0 investors
PTX is a biotech company developing therapeutic solutions to mitigate adverse side effects associated with cancer chemotherapy and other medical treatments. The company focuses on improving patient quality of life during medical therapies through drug development.
0 investors
0 investors
0 investors
Play-it Health builds Plan-it Med, a remote patient monitoring platform that tracks patient biometrics and improves adherence to medications, appointments, and patient education. It provides healthcare providers with secure clinician-patient communication tools (calls, telehealth, messaging) and support for billing RPM, CCM, and TCM under Medicare CPT codes.
0 investors
0 investors
0 investors
0 investors
Cerenome operates an integrated central nervous system (CNS) oncology platform that combines precision diagnostics, targeted radiotherapeutics, and clinical data to improve how CNS cancers are detected, treated, and monitored. Evolving from work begun at Plus Therapeutics in 2020, it serves patients with CNS cancers.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
PNP Therapeutics is a clinical-stage biopharmaceutical company developing Gedeptin, a platform technology for cancer treatment that programs tumors to generate their own chemotherapy through a patented enzyme and prodrug system. The company targets patients with solid tumors including prostate, breast, colon, lung, brain, melanoma, pancreas, ovarian, and kidney cancers.
0 investors
0 investors
0 investors
0 investors